Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
52 hedge funds and large institutions have $217M invested in Poseida Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$106M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$55.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.4M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$14.2M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$12M |
Top Sellers
PSTX Hedge Fund Activity: Q3 2020 in Review
52 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2020, worth a combined $217M.
Buyers outnumbered sellers: 52 funds opened new PSTX positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $106M.
- 52 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $217M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2020.
- 52 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2020 and 0 closed out, a net change of +52 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2020 was Fidelity Investments, an estimated $106M added.
Based on aggregated 13F filings for Q3 2020.